16

labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally

  • Upload
    others

  • View
    1

  • Download
    0

Embed Size (px)

Citation preview

Page 1: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 2: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 3: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 4: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 5: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 6: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 7: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 8: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 9: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 10: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 11: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 12: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 13: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 14: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 15: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally
Page 16: labma.uii.ac.id · 2020. 9. 4. · stroke (AIS). It reduces the efficacy or thromboIYSiS. increases infarct size. and worsens clinical outcome¶ Insulin-based therapies have generally